Document is current
Any future updates will be listed below
-
Authors
Busschots, Dana http://orcid.org/0000-0003-0887-4119
Bielen, Rob
Koc, Özgür M.
Heyens, Leen
Dercon, Eefje
Verrando, Rita
Janssens, Filip
Van den Bergh, Luc
Van Lint, Peter
Bruckers, Liesbeth
Nevens, Frederik
Robaeys, Geert
- License Information
-
More Information
Article History
Received: 2 December 2020
Accepted: 8 August 2021
First Online: 20 August 2021
Declarations
:
: The study was first approved by the Ethical Committees of Ziekenhuis Oost-Limburg, Genk, and Hasselt University (16/014 U). An amendment was approved to include the study sites of all hospitals in 2017 and perform the services by an HCV case manager. The study protocol was registered at clinicaltrials.gov (NCT03106194). The study was conducted following the provisions of the Declaration of Helsinki and its amendments. Good clinical practice guidelines were followed throughout the study, and all participants provided written informed consent.
: Not applicable.
: D.B. has received travel grants from AbbVie and Gilead Sciences and a research grant from Gilead. R.B. has received travel grants from AbbVie, Gilead Sciences and MSD and research grants from Gilead and MSD. Ö.K. has received a travel grant and research grants from Gilead. F.N. has received research grants, consultancy agreements and travel grants from UCB, Ipsen, Roche, Astellas, Ferring, Novartis, Janssen-Cilag, Abbvie, Gilead, CAF, Intercept, Gore, BMS, MSD, Promethera Biosciences, Ono Pharma, Durect. G.R. has received research grants from AbbVie, Janssen Pharmaceuticals, MSD, and has acted as a consultant/advisor for AbbVie, BMS, Gilead Sciences and MSD. The other co-authors report no conflict of interest.
